Conor gains in UK
This article was originally published in The Gray Sheet
Executive Summary
UK High Court of Justice invalidates Boston Scientific-licensed Angiotech patent for paclitaxel-eluting stent in response to a revocation request by Conor Medsystems. Angiotech says it will appeal the decision, which only affects the UK patent. Conor received a CE Mark for marketing its CoStar paclitaxel-eluting stent in Europe Feb. 17 (1"The Gray Sheet" Feb. 20, 2006, p. 7)...
You may also be interested in...
Conor CoStar Cleared For European Launch; Firm Modifies U.S. Trial Design
Conor Medsystems will launch its CoStar paclitaxel-eluting, cobalt-chromium coronary stent in Europe, having just received a CE mark, the firm said Feb. 17
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.